On November 2, 2023 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported that it will be attending Bio-Europe, the largest biopharmaceutical industry partnering event in Europe, taking place November 6 – 8, 2023 in Munich, Germany (Press release, Actinium Pharmaceuticals, NOV 2, 2023, View Source [SID1234636720]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Actinium is advancing a pipeline of differentiated, clinical-stage targeted radiotherapeutics including Iomab-B for bone marrow transplant conditioning, which met the primary endpoint in the Phase 3 SIERRA trial and is being prepared for a BLA filing, Iomab-ACT for conditioning prior to cell and gene therapy and Actimab-A as a therapeutic for relapsed or refractory acute myeloid leukemia that has shown backbone therapy potential in combinations. Actinium is also advancing novel solid tumor programs leveraging its industry leading experience with the alpha-particle payload Actinium-225 and intellectual property including linker technology and Actinium-225 manufacturing.

Members of Actinium’s senior leadership team will be available for one-on-one meetings during the in-person meeting as well as the digital partnering taking place November 14-15, 2023. To request a meeting with Actinium through partneringONE https://informaconnect.com/bioeurope/. Interested parties may also contact the Company directly to schedule in person or virtual meetings by emailing Actinium.